Glucotrack, Inc. (GCTK): Completion of Acquisition or Disposition of Assets
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 Execution Copy AGREEMENT AND PLAN OF MERGER dated as of July 14, 2026 by and among GLUCOTRACK, INC., as the Acquiror GLUCOTRACK MERGER SUB, INC., as the Merger Sub LOKAHI THERAPEUTICS, INC., as the Company, GLUCOTRACK TECHNOLOGIES INC., as Op
How this was made
The 30-second read
Why it matters
Because the filing explicitly reports completion of the acquisition/disposition (Item 2.01), traders should focus on post-close effects such as equity conversion, governance changes, and any newly created obligations (Item 2.03).
Market read
This is a primary-source transaction completion update for GCTK, which can drive near-term repricing around deal mechanics and integration expectations.
What to watch
Key trading drivers are missing from the excerpt, including purchase price/consideration, share conversion mechanics, any direct financial obligation terms (Item 2.03), and whether there are contingent liabilities or financing conditions.
Background
The 8-K references an Agreement and Plan of Merger dated July 14, 2026 among Glucotrack, Inc. (acquiror), Glucotrack Merger Sub, Lokahi Therapeutics, and Glucotrack Technologies (operating sub).
Ticker impact
Glucotrack, Inc. (GCTK) filed an 8-K stating completion of an acquisition/disposition of assets via an agreement and plan of merger dated July 14, 2026.
Likely choppy post-close trading as investors digest merger terms and any resulting share conversion or obligations; direction depends on deal economics not shown in the excerpt.
The filing confirms completion (Item 2.01) and a merger structure (Merger Sub merging into the Company), but the provided text excerpt does not include consideration, share conversion ratios, or financial impact details.
Market effects
Limited from the excerpt; merger completion may affect competitive positioning within the acquirer’s operating niche, but no sector-wide datapoints are provided.
None indicated in the excerpt.
None indicated in the excerpt.
Counterpoint
Completion alone may not change fundamentals materially if consideration is mostly stock or if the acquired business is already expected; without deal economics, the market may re-rate only modestly.
Key entities
- public_companyGlucotrack, Inc.
Subject of the 8-K; reports completion of the merger/acquisition transaction.
- companyLokahi Therapeutics, Inc.
Named as the Company in the merger agreement; becomes the surviving corporation per the excerpt.
- companyGlucotrack Merger Sub, Inc.
Merger Sub that merges into the Company under the plan.
